Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. (June 2018)
- Record Type:
- Journal Article
- Title:
- Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. (June 2018)
- Main Title:
- Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
- Authors:
- Razavi-Shearer, Devin
Gamkrelidze, Ivane
Nguyen, Mindie H
Chen, Ding-Shinn
Van Damme, Pierre
Abbas, Zaigham
Abdulla, Maheeba
Abou Rached, Antoine
Adda, Danjuma
Aho, Inka
Akarca, Ulus
Hasan, Fuad
Al Lawati, Faryal
Al Naamani, Khalid
Al-Ashgar, Hamad Ibrahim
Alavian, Seyed M
Alawadhi, Sameer
Albillos, Agustin
Al-Busafi, Said A
Aleman, Soo
Alfaleh, Faleh Z
Aljumah, Abdulrahman A
Anand, Anil C
Anh, Nguyen Thu
Arends, Joop E
Arkkila, Perttu
Athanasakis, Kostas
Bane, Abate
Ben-Ari, Ziv
Berg, Thomas
Bizri, Abdul R
Blach, Sarah
Brandão Mello, Carlos E
Brandon, Samantha M
Bright, Bisi
Bruggmann, Philip
Brunetto, Maurizia
Buti, Maria
Chan, Henry L Y
Chaudhry, Asad
Chien, Rong-Nan
Choi, Moon S
Christensen, Peer B
Chuang, Wan-Long
Chulanov, Vladimir
Clausen, Mette R
Colombo, Massimo
Cornberg, Markus
Cowie, Benjamin
Craxi, Antonio
Croes, Esther A
Cuellar, Diego Alberto
Cunningham, Chris
Desalegn, Hailemichael
Drazilova, Sylvia
Duberg, Ann-Sofi
Egeonu, Steve S
El-Sayed, Manal H
Estes, Chris
Falconer, Karolin
Ferraz, Maria L G
Ferreira, Paulo R
Flisiak, Robert
Frankova, Sona
Gaeta, Giovanni B
García-Samaniego, Javier
Genov, Jordan
Gerstoft, Jan
Goldis, Adrian
Gountas, Ilias
Gray, Richard
Guimarães Pessôa, Mário
Hajarizadeh, Behzad
Hatzakis, Angelos
Hézode, Christophe
Himatt, Sayed M
Hoepelman, Andy
Hrstic, Irena
Hui, Yee-Tak T
Husa, Petr
Jahis, Rohani
Janjua, Naveed Z
Jarčuška, Peter
Jaroszewicz, Jerzy
Kaymakoglu, Sabahattin
Kershenobich, David
Kondili, Loreta A
Konysbekova, Aliya
Krajden, Mel
Kristian, Pavol
Laleman, Wim
Lao, Wai-cheung C
Layden, Jen
Lazarus, Jeffrey V
Lee, Mei-Hsuan
Liakina, Valentina
Lim, Young-Suk S
Loo, Ching-kong K
Lukšić, Boris
Malekzadeh, Reza
Malu, Abraham O
Mamatkulov, Adkhamjon
Manns, Michael
Marinho, Rui T
Maticic, Mojca
Mauss, Stefan
Memon, Muhammad S
Mendes Correa, Maria C
Mendez-Sanchez, Nahum
Merat, Shahin
Metwally, Ammal M
Mohamed, Rosmawati
Mokhbat, Jacques E
Moreno, Christophe
Mossong, Joel
Mourad, Fadi H
Müllhaupt, Beat
Murphy, Kimberly
Musabaev, Erkin
Nawaz, Arif
Nde, Helen M
Negro, Francesco
Nersesov, Alexander
Nguyen, Van Thi Thuy
Njouom, Richard
Ntagirabiri, Renovat
Nurmatov, Zuridin
Obekpa, Solomon
Ocama, Ponsiano
Oguche, Stephen
Omede, Ogu
Omuemu, Casimir
Opare-Sem, Ohene
Opio, Christopher K
Örmeci, Necati
Papatheodoridis, George
Pasini, Ken
Pimenov, Nikolay
Poustchi, Hossein
Quang, Trân D
Qureshi, Huma
Ramji, Alnoor
Razavi-Shearer, Kathryn
Redae, Berhane
Reesink, Henk W
Rios, Cielo Yaneth
Rjaskova, Gabriela
Robbins, Sarah
Roberts, Lewis R
Roberts, Stuart K
Ryder, Stephen D
Safadi, Rifaat
Sagalova, Olga
Salupere, Riina
Sanai, Faisal M
Sanchez-Avila, Juan F
Saraswat, Vivek
Sarrazin, Christoph
Schmelzer, Jonathan D
Schréter, Ivan
Scott, Julia
Seguin-Devaux, Carole
Shah, Samir R
Sharara, Ala I
Sharma, Manik
Shiha, Gamal E
Shin, Tesia
Sievert, William
Sperl, Jan
Stärkel, Peter
Stedman, Catherine
Sypsa, Vana
Tacke, Frank
Tan, Soek S
Tanaka, Junko
Tomasiewicz, Krzysztof
Urbanek, Petr
van der Meer, Adriaan J
Van Vlierberghe, Hans
Vella, Stefano
Vince, Adriana
Waheed, Yasir
Waked, Imam
Walsh, Nicholas
Weis, Nina
Wong, Vincent W
Woodring, Joseph
Yaghi, Cesar
Yang, Hwai-I
Yang, Chung-Lin
Yesmembetov, Kakharman
Yosry, Ayman
Yuen, Man-Fung
Yusuf, Muhammed Aasim M
Zeuzem, Stefan
Razavi, Homie
… (more) - Abstract:
- Summary: Background: The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (HBV) infection, existing therapies to control viral replication and prophylaxis to minimise mother-to-child transmission make elimination of HBV feasible. We aimed to estimate the national, regional, and global prevalence of HBsAg in the general population and in the population aged 5 years in 2016, as well as coverage of prophylaxis, diagnosis, and treatment. Methods: In this modelling study, we used a Delphi process that included a literature review in PubMed and Embase, followed by interviews with experts, to quantify the historical epidemiology of HBV infection. We then used a dynamic HBV transmission and progression model to estimate the country-level and regional-level prevalence of HBsAg in 2016 and the effect of prophylaxis and treatment on disease burden. Findings: We developed models for 120 countries, 78 of which were populated with data approved by experts. Using these models, we estimated that the global prevalence of HBsAg in 2016 was 3·9% (95% uncertainty interval [UI] 3·4–4·6), corresponding to 291 992 000 (251 513 000–341 114 000) infections. Of these infections, around 29 million (10%) were diagnosed, and only 4·8 million (5%) of 94 million individuals eligible for treatment actually received antiviral therapy. Around 1·8 (1·6–2·2) million infections were in childrenSummary: Background: The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (HBV) infection, existing therapies to control viral replication and prophylaxis to minimise mother-to-child transmission make elimination of HBV feasible. We aimed to estimate the national, regional, and global prevalence of HBsAg in the general population and in the population aged 5 years in 2016, as well as coverage of prophylaxis, diagnosis, and treatment. Methods: In this modelling study, we used a Delphi process that included a literature review in PubMed and Embase, followed by interviews with experts, to quantify the historical epidemiology of HBV infection. We then used a dynamic HBV transmission and progression model to estimate the country-level and regional-level prevalence of HBsAg in 2016 and the effect of prophylaxis and treatment on disease burden. Findings: We developed models for 120 countries, 78 of which were populated with data approved by experts. Using these models, we estimated that the global prevalence of HBsAg in 2016 was 3·9% (95% uncertainty interval [UI] 3·4–4·6), corresponding to 291 992 000 (251 513 000–341 114 000) infections. Of these infections, around 29 million (10%) were diagnosed, and only 4·8 million (5%) of 94 million individuals eligible for treatment actually received antiviral therapy. Around 1·8 (1·6–2·2) million infections were in children aged 5 years, with a prevalence of 1·4% (1·2–1·6). We estimated that 87% of infants had received the three-dose HBV vaccination in the first year of life, 46% had received timely birth-dose vaccination, and 13% had received hepatitis B immunoglobulin along with the full vaccination regimen. Less than 1% of mothers with a high viral load had received antiviral therapy to reduce mother-to-child transmission. Interpretation: Our estimate of HBV prevalence in 2016 differs from previous studies, potentially because we took into account the effect of infant prophylaxis and early childhood vaccination, as well as changing prevalence over time. Although some regions are well on their way to meeting prophylaxis and prevalence targets, all regions must substantially scale-up access to diagnosis and treatment to meet the global targets. Funding: John C Martin Foundation. … (more)
- Is Part Of:
- Lancet gastroenterology and hepatology. Volume 3:Number 6(2018)
- Journal:
- Lancet gastroenterology and hepatology
- Issue:
- Volume 3:Number 6(2018)
- Issue Display:
- Volume 3, Issue 6 (2018)
- Year:
- 2018
- Volume:
- 3
- Issue:
- 6
- Issue Sort Value:
- 2018-0003-0006-0000
- Page Start:
- 383
- Page End:
- 403
- Publication Date:
- 2018-06
- Journal URLs:
- http://www.sciencedirect.com/ ↗
- DOI:
- 10.1016/S2468-1253(18)30056-6 ↗
- Languages:
- English
- ISSNs:
- 2468-1253
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5146.081000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 6426.xml